文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

艾曲泊帕联合阿扎胞苷治疗高危骨髓增生异常综合征及相关疾病患者的 Ib 期研究(ELASTIC 研究)

Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).
PubMed 文献 · Br J Haematol · 2022-08-02

ELASTIC 研究采用 3+3 队列设计,评估艾曲泊帕联合阿扎胞苷治疗基线血小板 <150×10⁹/L 的高危骨髓增生异常综合征及相关疾病患者的安全性。31 例患者中未出现剂量限制性毒性,最大耐受剂量为 300 mg;第 8 天骨髓原始细胞一过性升高常见,但艾曲泊帕单药治疗后无患者出现方案定义的疾病进展。作者结论认为该联合方案在传统不良事件报告意义上安全,但鉴于 SUPPORT 研究及本研究的描述性疗效发现,高危疾病的进一步联合研究应谨慎考虑。

要点

  • 31 例患者中未出现剂量限制性毒性,最大耐受剂量为 300 mg。
  • 第 8 天骨髓原始细胞一过性升高常见,但艾曲泊帕单药后无方案定义的疾病进展。
  • 三个和六个治疗周期后的骨髓缓解率分别为 32% 和 29%。

核心结论

  • 艾曲泊帕联合阿扎胞苷在传统不良事件报告定义的安全性指标方面是安全的。
  • 鉴于 SUPPORT 研究和本研究关于疗效的描述性发现,高危疾病的进一步联合研究应谨慎考虑。

研究设计与样本

  • 采用 3+3 队列设计的 Ib 期研究,纳入基线血小板 <150×10⁹/L 的高危骨髓增生异常综合征及相关疾病患者。
  • 艾曲泊帕剂量范围为 25 至 300 mg,先进行 8 天艾曲泊帕前驱期,随后接受两个周期联合治疗。
  • 共 31 例患者。

主要发现

  • 31 例患者中未出现剂量限制性毒性,最大耐受剂量为 300 mg。
  • 第 8 天骨髓原始细胞一过性升高常见,但艾曲泊帕单药治疗后无患者出现方案定义的疾病进展。
  • 三个和六个治疗周期后的骨髓缓解率分别为 32% 和 29%。
  • 在低于最大耐受剂量治疗的患者中 70%、在最大耐受剂量治疗的患者中 36% 在第二周期结束时达到改良国际工作组 2006 血小板反应。
  • 基线时不依赖血小板输注的患者中,在最大耐受剂量治疗的患者有 67% 在最初两个治疗周期内变为依赖输注。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treating adverse risk myelodysplastic syndromes with azacitidine exacerbates thrombocytopenia. We report a study of eltrombopag in combination with azacitidine using a 3 + 3 cohort design. Patients with baseline platelets of <150 × 109 /l received eltrombopag ranging from 25 to 300 mg. An 8-day pre-phase of eltrombopag was followed by two cycles of combined therapy. Amongst 31 patients, there were no dose-limiting toxicities. The maximum tolerated dose (MTD) was 300 mg. Transient increases in bone marrow blasts at day 8 were common but no patient had protocol-defined progression following eltrombopag monotherapy. Marrow response rates after three and six treatment cycles were 32% and 29% respectively. In all, 70% of patients treated below and 36% treated at the MTD achieved a modified International Working Group 2006 platelet response at the end of cycle two. Of the platelet transfusion independent patients at baseline, 67% treated at the MTD became transfusion dependent during the first two cycles of treatment. Apart from lack of disease progression, our findings concur with a previously reported Phase III study (A StUdy of eltromboPag in myelodysPlastic SyndrOmes Receiving azaciTidine [SUPPORT]). We conclude that eltrombopag/azacitidine is safe in terms of conventional measures defined by adverse-event reporting. However, in light of SUPPORT and our own descriptive findings regarding efficacy, further combination studies in high-risk disease should be considered with caution.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Sternberg A, Boucher R, Coulthard HC, et al. Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study). Br J Haematol. 2022. PMID: 35918828. doi:10.1111/bjh.18389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。